About AstraZeneca plc (LON:AZN)
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: LON:AZN
- CUSIP: N/A
- Web: www.astrazeneca.com/
Capitalization:- Market Cap: £65.52 billion
- Outstanding Shares: 1,266,000,000
Average Prices:- 50 Day Moving Avg: GBX 4,904.35
- 200 Day Moving Avg: GBX 4,912.64
- 52 Week Range: GBX 3,996 - GBX 5,520
P/E:- Trailing P/E Ratio: 16.97
- P/E Growth: 4.82
Sales & Book Value:- Annual Revenue: £21.74 billion
- Price / Sales: 3.01
- Book Value: GBX 10.78 per share
- Price / Book: 4.80
Dividend:
Profitability:- EBITDA: £5.91 billion
- Net Margins: 8.83%
- Return on Equity: 14.36%
- Return on Assets: 2.84%
Misc:- Average Volume: 2.52 million shs.
Frequently Asked Questions for AstraZeneca plc (LON:AZN)
What is AstraZeneca plc's stock symbol?
AstraZeneca plc trades on the London Stock Exchange (LON) under the ticker symbol "AZN."
How often does AstraZeneca plc pay dividends? What is the dividend yield for AstraZeneca plc?
AstraZeneca plc announced a dividend on Thursday, July 27th. Investors of record on Thursday, August 10th will be paid a dividend of GBX 68.90 per share on Monday, September 11th. This represents a yield of 1.35%. The ex-dividend date is Thursday, August 10th. The official announcement can be seen at this link. View AstraZeneca plc's Dividend History.
Where is AstraZeneca plc's stock going? Where will AstraZeneca plc's stock price be in 2017?
21 equities research analysts have issued 1 year target prices for AstraZeneca plc's shares. Their forecasts range from GBX 3,800 to GBX 6,500. On average, they expect AstraZeneca plc's share price to reach GBX 5,202.29 in the next year. View Analyst Ratings for AstraZeneca plc.
Who are some of AstraZeneca plc's key competitors?
Some companies that are related to AstraZeneca plc include Novo Nordisk A/S (NVO), Sanofi (SNY), Celgene Corporation (CELG), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), GlaxoSmithKline plc (GSK), Shire PLC (SHPG), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Catalent (CTLT), Patheon NV (PTHN), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX) and Opko Health (OPK).
Who are AstraZeneca plc's key executives?
AstraZeneca plc's management team includes the folowing people:
- Pascal Soriot, Executive Director and Chief Executive Officer
- Marc Dunoyer, Executive Director, Chief Financial Officer
- Fiona Cicconi, Executive Vice-President, Human Resources
- Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
- Pam P. Cheng, Executive Vice President - Operations and Information Technology
- Ruud Dobber, Executive Vice President, North America
- Bahija Jallal Ph.D., Executive Vice President, MedImmune
- Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
- Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
- Leon Wang, Executive Vice President - Asia Pacific
How do I buy AstraZeneca plc stock?
Shares of AstraZeneca plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is AstraZeneca plc's stock price today?
One share of AstraZeneca plc stock can currently be purchased for approximately GBX 5,175.
MarketBeat Community Rating for AstraZeneca plc (LON AZN)MarketBeat's community ratings are surveys of what our community members think about AstraZeneca plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for AstraZeneca plc (LON:AZN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Sell Ratings, 6 Hold Ratings, 12 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.43) |
| Consensus Price Target: | GBX 5,202.29 |
Consensus Price Target History for AstraZeneca plc (LON:AZN)
Analysts' Ratings History for AstraZeneca plc (LON:AZN)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 10/20/2017 | Morgan Stanley | Set Price Target | Neutral | GBX 4,700 |  |
| 10/18/2017 | J P Morgan Chase & Co | Set Price Target | Neutral | GBX 4,500 | |
| 10/17/2017 | Shore Capital | Reiterated Rating | Hold | | |
| 10/17/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell | GBX 3,800 | |
| 10/16/2017 | Credit Suisse Group | Upgrade | Neutral -> Outperform | GBX 4,800 -> GBX 5,800 | |
| 10/16/2017 | Jefferies Group LLC | Boost Price Target | Hold | GBX 4,900 -> GBX 5,100 | |
| 10/11/2017 | Deutsche Bank AG | Reiterated Rating | Buy | GBX 5,600 | |
| 10/9/2017 | HSBC Holdings plc | Boost Price Target | Reduce | GBX 4,100 -> GBX 4,150 | |
| 10/5/2017 | Barclays PLC | Reiterated Rating | Overweight | GBX 6,300 | |
| 9/25/2017 | BNP Paribas | Set Price Target | Buy | GBX 5,800 | |
| 9/25/2017 | Sanford C. Bernstein | Set Price Target | Buy | GBX 5,780 | |
| 9/21/2017 | Societe Generale | Reiterated Rating | Buy | | |
| 9/19/2017 | Berenberg Bank | Set Price Target | Buy | GBX 5,800 | |
| 9/14/2017 | Liberum Capital | Downgrade | Buy -> Hold | GBX 4,800 -> GBX 5,000 | |
| 9/13/2017 | Citigroup Inc. | Set Price Target | Buy | GBX 6,000 | |
| 9/11/2017 | Kepler Capital Markets | Reiterated Rating | Buy | GBX 5,200 | |
| 9/11/2017 | Bryan, Garnier & Co | Upgrade | Buy | GBX 4,700 -> GBX 5,380 | |
| 9/6/2017 | Natixis | Upgrade | Neutral -> Buy | GBX 5,000 -> GBX 5,738 | |
| 8/9/2017 | Investec | Upgrade | Hold -> Buy | GBX 5,000 -> GBX 4,900 | |
| 7/28/2017 | Beaufort Securities | Downgrade | Sell | GBX 3,900 | |
| 7/27/2017 | S&P Global | Set Price Target | Neutral | GBX 4,500 | |
| 6/24/2016 | Independent Research GmbH | Set Price Target | Sell | GBX 3,650 | |
| 5/10/2016 | Oddo Securities | Reiterated Rating | Buy | GBX 5,400 | |
| 5/5/2016 | Charles Stanley | Upgrade | Strong-Buy | | |
| 3/23/2016 | Nomura | Lower Price Target | Hold | GBX 4,880 -> GBX 4,350 | |
| 2/12/2016 | Baader Bank | Reiterated Rating | Hold | GBX 4,400 | |
| 2/9/2016 | AlphaValue | Upgrade | Buy | GBX 4,640 | |
| 2/4/2016 | S&P Equity Research | Set Price Target | Neutral | GBX 4,500 | |
| 2/2/2016 | Handelsbanken | Reiterated Rating | Accumulate | GBX 5,220.30 | |
| 1/28/2016 | Pareto Securities | Reiterated Rating | Sell | GBX 3,855.35 | |
| 1/27/2016 | Swedbank | Reiterated Rating | Buy | GBX 5,115.47 | |
| 1/13/2016 | Nordea Equity Research | Reiterated Rating | Hold | GBX 4,698.35 | |
(Data available from 10/20/2015 forward)
Earnings History for AstraZeneca plc (LON:AZN)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for AstraZeneca plc (LON:AZN)Current Year EPS Consensus Estimate: $3.77 EPS
Dividend History by Quarter for AstraZeneca plc (LON AZN)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/27/2017 | | GBX 68.90 | 1.35% | 8/10/2017 | 8/10/2017 | 9/11/2017 |
| 2/2/2017 | | GBX 150.20 | 3.52% | 2/16/2017 | 2/16/2017 | 3/20/2017 |
| 7/28/2016 | | GBX 68.70 | 1.37% | 8/11/2016 | 8/11/2016 | 9/12/2016 |
| 2/4/2016 | | GBX 131 | 3.16% | 2/18/2016 | 2/18/2016 | 3/21/2016 |
| 7/30/2015 | | GBX 57.50 | 1.33% | 8/13/2015 | 8/13/2015 | 9/14/2015 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for AstraZeneca plc (LON:AZN)Insider Trades by Quarter for AstraZeneca plc (LON:AZN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/27/2017 | Nazneen Rahman | Insider | Buy | 39 | GBX 4,370 | £1,704.30 | |
| 10/27/2015 | Courtois,Jean-Philippe | Insider | Buy | 900 | GBX 4,423 | £39,807 | |
| 8/28/2015 | Soriot,Pascal | Insider | Buy | 76,300 | GBX 3,960 | £3,021,480 | |
| 5/7/2015 | Marc Dunoyer | Insider | Buy | 10,000 | GBX 4,397 | £439,700 | |
| 4/30/2015 | Ann Cairns | Insider | Buy | 1,100 | GBX 4,455 | £49,005 | |
| 4/29/2015 | Shriti Vadera | Insider | Buy | 3,500 | GBX 4,563 | £159,705 | |
| 4/28/2015 | Graham Chipchase | Insider | Buy | 1,100 | GBX 4,606 | £50,666 | |
| 4/27/2015 | Bruce Burlington | Insider | Buy | 600 | GBX 4,662 | £27,972 | |
(Data available from 1/1/2013 forward)
Headline Trends for AstraZeneca plc (LON:AZN)
Latest Headlines for AstraZeneca plc (LON:AZN)
| Source: |
|
| Date | Headline |
|---|
 | AstraZeneca plc (AZN) Given a GBX 4,700 Price Target at Morgan Stanley
www.americanbankingnews.com - October 20 at 11:44 AM |
 | China biotech's 'coming out party' masks long road ahead
finance.yahoo.com - October 19 at 3:40 AM |
 | Hutchison China MediTech, AstraZeneca Present Savolitinib Combo Data
www.morningstar.co.uk - October 18 at 10:39 PM |
| TOP NEWS: AstraZeneca's Imfinzi Granted Priority Review In Lung Cancer
www.morningstar.co.uk - October 18 at 5:38 PM |
| AstraZeneca plc's (AZN) "Hold" Rating Reiterated at Shore Capital
www.americanbankingnews.com - October 17 at 6:30 AM |
 | Novo Nordisk diabetes drug works; no heart risk-FDA review
www.reuters.com - October 16 at 10:05 PM |
| AstraZeneca plc (AZN) PT Set at GBX 5,800 by Credit Suisse Group
www.americanbankingnews.com - October 16 at 7:20 AM |
| Drug Companies Fear Brexit Will Hit Medicine Trade
finance.yahoo.com - October 16 at 2:04 AM |
| 5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings - Yahoo Finance
finance.yahoo.com - October 15 at 9:04 PM |
 | Hold Rating for AstraZeneca (AZN) Retained - Investorplace.com (blog)
investorplace.com - October 15 at 2:06 AM |
| AstraZeneca plc (AZN) Given a GBX 4,550 Price Target at UBS AG
www.americanbankingnews.com - October 9 at 10:06 AM |
| AstraZeneca plc's (AZN) "Overweight" Rating Reiterated at Barclays PLC
www.americanbankingnews.com - October 8 at 11:16 AM |
| AstraZeneca plc (AZN) Rating Reiterated by Deutsche Bank AG
www.americanbankingnews.com - October 8 at 10:02 AM |
| FTSE scales two-month peak
finance.yahoo.com - October 6 at 8:38 AM |
| Drug industry gives up legal battle over new UK cost curbs
finance.yahoo.com - October 5 at 2:23 PM |
| AstraZeneca plc (AZN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - October 4 at 6:52 AM |
 | AstraZeneca's Bevespi Improves Lung Function in Phase III Study - Nasdaq
www.nasdaq.com - September 28 at 12:45 AM |
 | AstraZeneca's Bevespi Improves Lung Function in Phase III Study
www.zacks.com - September 27 at 7:44 PM |
| AstraZeneca plc (AZN) Given a GBX 5,800 Price Target at BNP Paribas
www.americanbankingnews.com - September 25 at 4:44 PM |
| Berenberg Bank Analysts Give AstraZeneca plc (AZN) a GBX 5,800 Price Target
www.americanbankingnews.com - September 24 at 2:08 PM |
| Societe Generale Reiterates "Buy" Rating for AstraZeneca plc (AZN)
www.americanbankingnews.com - September 23 at 5:22 PM |
 | Why I’d ditch this defensive dividend stock to buy AstraZeneca plc
www.msn.com - September 18 at 4:43 PM |
| AstraZeneca plc (AZN) PT Set at GBX 4,900 by Jefferies Group LLC
www.americanbankingnews.com - September 18 at 6:30 AM |
| AstraZeneca plc (AZN) Given a GBX 6,000 Price Target by Citigroup Inc. Analysts
www.americanbankingnews.com - September 17 at 7:38 PM |
| AstraZeneca plc (AZN) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - September 17 at 1:32 PM |
| Liberum Capital Downgrades AstraZeneca plc (AZN) to Hold
www.americanbankingnews.com - September 17 at 11:38 AM |
| Barclays PLC Analysts Give AstraZeneca plc (AZN) a GBX 6,300 Price Target
www.americanbankingnews.com - September 13 at 6:04 PM |
 | Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca ...
www.prnewswire.com - September 13 at 5:28 PM |
 | Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson
www.bizjournals.com - September 13 at 5:28 PM |
| AstraZeneca's Asthma Candidate Shows Promising Results
finance.yahoo.com - September 12 at 4:32 PM |
| AstraZeneca plc (AZN) Given a GBX 4,550 Price Target by UBS AG Analysts
www.americanbankingnews.com - September 12 at 12:40 AM |
| AstraZeneca plc (AZN) Given a GBX 5,300 Price Target at BNP Paribas
www.americanbankingnews.com - September 12 at 12:08 AM |
 | AstraZeneca Spikes After Lung Cancer Treat Study Shows 'Encouraging' Results
www.thestreet.com - September 11 at 4:53 PM |
 | AstraZeneca Wins in Cancer by Going Its Own Way
www.bloomberg.com - September 11 at 4:53 PM |
 | AstraZeneca (AZN) Presents At European Society For Medical Oncology Annual Congress - Slideshow
seekingalpha.com - September 11 at 4:52 PM |
| AstraZeneca plc's (AZN) Buy Rating Reiterated at Berenberg Bank
www.americanbankingnews.com - September 11 at 9:30 AM |
| AstraZeneca plc (AZN) Given "Neutral" Rating at J P Morgan Chase & Co
www.americanbankingnews.com - September 9 at 8:18 PM |
| AstraZeneca CEO, worried by Brexit, not signing UK government letter
finance.yahoo.com - September 9 at 4:03 PM |
| AstraZeneca CEO, worried by Brexit, not signing UK government letter
finance.yahoo.com - September 9 at 4:03 PM |
| AstraZeneca plc (AZN) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - September 9 at 6:26 AM |
| AstraZeneca rebuilds cancer drug hopes with new lung data
finance.yahoo.com - September 8 at 9:43 PM |
| [$$] AstraZeneca looks for boost from positive trials
finance.yahoo.com - September 8 at 9:43 PM |
| AstraZeneca shares tick higher on lung cancer drug study results
finance.yahoo.com - September 8 at 9:43 PM |
| Merck's immunotherapy, chemo mix shows extended lung cancer gains
finance.yahoo.com - September 7 at 9:26 PM |
 | AstraZeneca Announces Results From PATHWAY Phase IIb Trial Of Tezepelumab
www.rttnews.com - September 7 at 4:23 PM |
| AstraZeneca's COPD Candidate Duaklir Reports Positive Data
www.zacks.com - September 7 at 4:23 PM |
| Citigroup Inc. Reiterates GBX 6,000 Price Target for AstraZeneca plc (AZN)
www.americanbankingnews.com - September 7 at 7:18 AM |
| AstraZeneca plc (AZN) Upgraded by Natixis to "Buy"
www.americanbankingnews.com - September 6 at 7:20 AM |
| AstraZeneca plc (AZN) Receives "Neutral" Rating from J P Morgan Chase & Co
www.americanbankingnews.com - September 5 at 12:32 AM |
| Nikkei climbs to 2-week highs as U.S. data bolsters dollar-yen
finance.yahoo.com - August 31 at 3:38 AM |
AstraZeneca plc (AZN) Chart for Friday, October, 20, 2017
